Product Description
Mechanisms of Action: PA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Austria | Belgium | Chile | China | Croatia | Czech | Egypt | Germany | Hungary | Indonesia | Ireland | Italy | Latvia | Lebanon | Lithuania | Luxembourg | Morocco | Pakistan | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Taiwan | Thailand | Tunisia | Ukraine | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Pharmaceutical Research Institute Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20200755 | N/A |
Completed |
Type 2 Diabetes |
2020-05-25 |
|
CTR20192391 | N/A |
Completed |
Type 2 Diabetes |
2020-01-10 |
|
CTR20201163 | N/A |
Unknown Status |
Type 2 Diabetes |
None |
|
CTR20221264 | N/A |
Not yet recruiting |
Type 2 Diabetes |
None |